Amicus Therapeutics Inc/ US03152W1099 /
| 24/05/2024 22:00:00 | Chg. +0.1900 | Volume | Bid13:24:42 | Ask13:24:42 | High | Low |
|---|---|---|---|---|---|---|
| 9.6600USD | +2.01% | 3.17 mill. Turnover: 25.37 mill. |
9.1000Bid Size: 100 | 9.7000Ask Size: 600 | 9.6900 | 9.4200 |
GlobeNewswire
09/05
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
08/05
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
GlobeNewswire
01/05
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
20/03
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
GlobeNewswire
28/02
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
GlobeNewswire
15/02
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire
08/02
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga)...
GlobeNewswire
01/02
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
GlobeNewswire
07/01
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
GlobeNewswire
03/01
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
05/12/2023
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next Presiden...
GlobeNewswire
08/11/2023
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
GlobeNewswire
01/11/2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
GlobeNewswire
27/10/2023
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
GlobeNewswire
03/10/2023
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
GlobeNewswire
02/10/2023
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
GlobeNewswire
28/09/2023
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda f...
GlobeNewswire
28/09/2023
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
GlobeNewswire
21/09/2023
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice Preside...
GlobeNewswire
14/09/2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
01/09/2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
GlobeNewswire
29/08/2023
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
GlobeNewswire
15/08/2023
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
